Individual hospital-funded oncology drugs for the indications of cancer metastasising to bone, prostate cancer with metastasis and skin cancer with metastasis.

The agreement period is nine months, from 1.11.2015 to 1.8.2016, with the possibility of extension of the agreement period until 30.11.2016 and with the possibility of further extension until 28.2.2017. Information about any extensions will be given 3 months prior to the expiry of the agreement.

The Contracting Authority uses Mercell Sourcing Service. To express your interest and gain access to any documents, please click on the link below or copy and paste the link into your browser. [[http://permalink.mercell.com/50350392.aspx]]. Then follow the instructions on the website.